Selank: Anxiety-First, Cognition-Adjacent

The short version

Selank is a synthetic heptapeptide — seven amino acids long — with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It starts from tuftsin, a naturally occurring immune-regulatory tetrapeptide fragment of immunoglobulin G, and adds a C-terminal Pro-Gly-Pro tail that slows enzymatic breakdown. The result is a compound that, in animal studies and limited Russian clinical research, reduces anxiety without the sedation or dependence associated with benzodiazepines ^[6].

Here is the honest part. Most of the published evidence originates from a small group of Russian institutions, largely in Russian-language journals. The single clinical study in patients with generalized anxiety disorder ^[6] reported a favorable anxiolytic effect, but independent Western replication is essentially absent. Selank is not approved by the FDA or EMA for any indication. It is sold in the United States only as a research chemical. This page summarizes the published science; it is not medical advice and lists no human dose.

What it is

Selank is also catalogued as TP-7 and referred to as a tuftsin analogue or heptapeptide Selank. The parent peptide tuftsin (Thr-Lys-Pro-Arg) is a tetrapeptide fragment of the heavy chain of immunoglobulin G with documented immunostimulatory and modestly anxiolytic properties. The C-terminal Pro-Gly-Pro extension in Selank slows enzymatic hydrolysis, giving the compound a longer functional half-life than the parent tetrapeptide while preserving and extending the anxiolytic profile.

Selank is not a natural body product you can extract; it is a synthetic research peptide. Outside Russia, it is handled as a research chemical with no approved drug or supplement status in any major Western jurisdiction.

How it works

Animal and in vitro research attributes Selank's effects to several non-benzodiazepine mechanisms.

GABAergic modulation. A 2018 review established that Selank acts as a positive allosteric modulator of GABA receptor binding — it enhances the binding of GABA to its receptor in a subtype-selective, concentration-dependent way, while also being able to block the modulating activity of diazepam and olanzapine at those same sites ^[1]. This explains why animal studies combining Selank with diazepam produce the largest anxiety reduction: the two compounds hit related but distinct sites ^[2].

Gene expression in GABAergic pathways. In rat frontal cortex, a single administration changed the expression of genes involved in GABAergic neurotransmission, with 45 genes shifting significantly at 1 hour and 22 at 3 hours; the direction of change correlated positively with the changes produced by GABA itself ^[3].

Enkephalin stabilization. Selank dose-dependently inhibited the enzymatic hydrolysis of plasma enkephalins in human plasma in vitro (IC50 approximately 15 micromolar), proposing that by protecting endogenous enkephalins from degradation it extends opioid-mediated anxiolysis ^[7].

Neurotrophin and monoamine effects. Intranasal Selank increased BDNF expression in the rat hippocampus in vivo ^[4], and the compound is also described as altering serotonin and dopamine turnover in animal models.

Immunomodulation. As a tuftsin analog, Selank modulates the Th1/Th2 cytokine balance and IL-6 expression, characterizing it as an immunomodulator in addition to its anxiolytic profile ^[5].

What the research shows

GABAergic mechanism (2018 review). The most detailed mechanistic account establishes positive allosteric modulation of GABA receptor binding, with concentration-dependent and subtype-selective effects distinct from benzodiazepines, and a capacity to block the modulatory action of diazepam and olanzapine — indicating distinct but overlapping binding sites ^[1].

Stress model (rats, 2017). In an unpredictable chronic mild stress model, Selank combined with diazepam outperformed either compound alone in reducing anxiety-related behavior, with the combined treatment most effectively restoring pre-stress behavioral baselines ^[2]. This supports GABAergic interaction as a valid mechanism.

Gene expression (rat frontal cortex, 2016). Administration produced significant changes in GABAergic-neurotransmission gene expression at 1 and 3 hours, with a positive correlation between Selank-induced and GABA-induced gene changes — the first transcriptomic evidence linking Selank directly to the GABAergic system ^[3].

BDNF regulation (rat hippocampus, 2008). Intranasal Selank increased BDNF expression in the rat hippocampus in vivo, linking the peptide to neurotrophic and neuroplasticity-associated signaling ^[4].

Immunomodulation (human patients, 2008). In patients with anxiety-asthenic disorders, Selank shifted the Th1/Th2 cytokine balance and modulated peripheral-blood IL-6 expression, supporting an immunomodulatory role alongside its anxiolytic action ^[5].

Clinical anxiolytic study (human patients with GAD, 2008). The most clinically relevant study reported that intranasal Selank in patients with generalized anxiety disorder produced an anxiolytic and mildly activating effect comparable to a benzodiazepine comparator, without sedation, cognitive impairment, or withdrawal ^[6]. This is a single Russian study; no independent Western trials have replicated it.

Enkephalin inhibition (human plasma in vitro, 2001). Dose-dependent inhibition of enkephalin-degrading enzyme activity in human plasma supported enkephalinase inhibition as a second anxiolytic mechanism, with an IC50 of approximately 15 micromolar ^[7].

Reported effects, cautions & safety

The following community reports are compiled from nootropic forums, peptide-user guides, and biohacker blogs. They are anecdotal, not clinical evidence, and are presented separately from the cited research findings above.

What users commonly report (anecdotal):

• Calm without sedation — The most consistent account is anxiety softening without the heavy fog of benzodiazepines or the emotional flatness of SSRIs. Users describe the volume on anxious thoughts turning down while the mind stays clear.
• Reduced situational anxiety — Many users take it before high-pressure events — presentations, exams, difficult conversations — and report markedly fewer nerves and lower anticipatory build-up.
• Fast onset intranasally — A shift is commonly noticed within 20 to 40 minutes via the intranasal route, making it useful as an as-needed tool before stressful events.
• Calm but sharp focus — A "calm but sharp" state is frequently described, with easier concentration once anxious mental chatter quiets.
• Mood lift over time — Many report a gradual mood lift and a more even-keeled baseline that builds over one to two weeks of regular use.
• Short per-dose duration — A very common complaint is that the noticeable effect lasts only a few hours. Non-response is also a real and commonly voiced part of the picture — some people report finishing a full vial and noticing nothing.
• Nasal irritation — Mild nasal dryness, burning, or stinging is one of the most commonly mentioned downsides with the intranasal route.

Cited cautions from the literature:

• Unregulated sourcing. Selank sold outside Russia is a research chemical with no guaranteed identity, purity, or sterility. Purity varies by supplier, and impurities carry risks unrelated to the peptide's studied pharmacology.
• Long-term human safety is not established. Human data are limited to small Russian studies over short courses. Short, single-region trials cannot speak to chronic use over months or years ^[6].
• Interaction unknowns. Selank touches GABAergic, opioid, monoaminergic, and immune systems. The potential for additive or unpredictable interactions with medications acting on those same systems is real and essentially unstudied in people ^{[1][2][3][5][7]}.
• Immune-signaling activity. As a tuftsin analog, Selank shifts cytokine balance. Downstream consequences in people with autoimmune conditions or immune-modulating medications are not characterized ^[5].
• Self-treating anxiety is not a substitute for professional care. Anxiety that is persistent or impairing has established evidence-based treatments; an unapproved research peptide is not equivalent ^[6].
• Not FDA-approved. Regulatory registration exists essentially only in Russia. In the US, Selank is sold strictly as a research chemical and is not intended for human consumption ^[6].

Where it fits in cognitive research

Among the two peptides on this desk, Selank is the lead and the more anxiety-focused. Its mechanistic story is unusually precise — GABAergic allosteric modulation, enkephalin stabilization, BDNF upregulation, and cytokine modulation are all described and cited — but the clinical record rests on a single Russian study in generalized anxiety disorder ^[6]. Its human evidence is thinner than many approved anxiolytics, not because the mechanism is implausible but because independent replication has not happened. Read alongside Semax, which works from a different angle — neurotrophin upregulation and neuroprotection rather than direct anxiety suppression — and the two compounds sketch quite different cognitive strategies. See the comparison page for how they line up.